IOM: International Agreement Needed to Curb False, Unsafe Pharmaceuticals

The Institute of Medicine identified a need for an international agreement to reduce the amount of falsified, substandard and counterfeit pharmaceuticals in a new report.

Advertisement

At the request of the Food and Drug Administration, an IOM committee examined the global effects of falsified, substandard and counterfeit drugs in a report, “Countering the Problem of Falsified and Substandard Drugs.”

Click here to read the full report on IOM’s recommendations in Becker’s ASC Review.

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The 2 KPIs that drive readmissions — and how hospitals act on them in real time

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenter: Nik Rao, Dexur

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.